Management of Patients on Ototoxic Medications

Pre-Treatment Assessment

The American Thoracic Society recommends obtaining baseline audiometry before initiating aminoglycoside therapy in all patients who can be tested 1, 2
Patients should be screened for hearing or balance difficulties through direct patient questioning 3
Renal function should be checked (serum creatinine, BUN, or creatinine clearance) as impaired renal function increases ototoxicity risk 1
High-risk patients, including the elderly, those with pre-existing renal impairment, diabetes, immunocompromised state, or previous exposure to ototoxic drugs, should be identified 1
A review of medication history for concomitant ototoxic agents (loop diuretics, cisplatin, vancomycin) is necessary to avoid potential interactions 4

Serum drug level monitoring is crucial, with target trough levels <5 mg/L for amikacin 1, 5
Peak and trough levels should be measured to ensure therapeutic efficacy while avoiding toxic accumulation 1
The American Thoracic Society recommends performing monthly audiometry until aminoglycoside treatment ceases 1, 2
Ototoxicity is defined as 20 dB loss from baseline at any one test frequency OR 10 dB loss at any two adjacent test frequencies 1, 5

The American Thoracic Society recommends discontinuing the aminoglycoside immediately if ototoxicity is detected on audiogram 1, 5, 2
Alternative options include reducing dosing frequency if discontinuation is not feasible, though hearing loss already occurred is likely permanent 1, 5
Patients should be instructed to stop treatment immediately and inform their prescriber if they develop tinnitus, vertigo, loss of balance, hearing loss, or auditory disturbances 1, 2, 5

The American Journal of Kidney Diseases recommends reducing dose and/or extending dosing interval when GFR <60 mL/min/1.73m² 4
Dosing should be based on ideal body weight in obese patients, not actual weight 1
Serum levels should be monitored closely as accumulation risk increases with renal dysfunction 1

Elderly patients are at higher risk for both nephrotoxicity and ototoxicity, and should be monitored more closely with consideration of dose reduction 1, 4
Patients with pre-existing hearing loss should be informed about the potential for further deterioration with macrolides, which is typically reversible 3
Aminoglycosides should be avoided in the second or third trimester of pregnancy due to the risk of vestibular or auditory nerve damage to the fetus 1, 5

Multiple aminoglycosides should never be combined due to increased toxicity risk and no clinical benefit 1, 5
Concurrent loop diuretics should be avoided as they potentiate ototoxicity 1, 4
Audiometry should not be delayed until symptoms appear, as damage may already be irreversible 1
Patient-reported symptoms alone are not reliable for monitoring, and objective audiometry is essential 1, 2

For patients over 59 years of age or with stage 3 CKD, the American Thoracic Society recommends reducing the dose to 10 mg/kg per day (maximum 750 mg) 6, 7
In renal insufficiency, the American Thoracic Society suggests maintaining the 12-15 mg/kg dose but reducing frequency to 2-3 times weekly rather than daily to preserve concentration-dependent killing while avoiding accumulation 6, 7
The American Thoracic Society advises against reducing the milligram dose below 12-15 mg/kg when extending intervals, as smaller doses may reduce efficacy by failing to achieve adequate peak concentrations 6, 7

For Pseudomonas infections, the American Thoracic Society recommends considering 2-3 months of intermittent amikacin (2-3 times weekly) in combination with other agents for extensive or drug-refractory disease 8

The American Thoracic Society warns against concurrent use of loop diuretics (furosemide, ethacrynic acid) as they potentiate ototoxicity 6

Amikacin produces a higher rate of cochlear toxicity than tobramycin or gentamicin, while causing less vestibular toxicity. (Evidence from a public‑health recommendation report) 9
High‑frequency hearing loss was observed in 24 % of patients receiving amikacin in a prospective study; no cases progressed to conversational‑level loss. (Prospective cohort) 9
A literature review reported a 1.5 % overall hearing‑loss incidence with amikacin, likely under‑estimated because of heterogeneous monitoring practices. (Systematic review) 9
Older age is consistently associated with an increased risk of aminoglycoside‑induced ototoxicity. (Observational data) 10
Renal impairment amplifies both ototoxic and nephrotoxic risk by allowing drug accumulation. (Public‑health recommendation report) 9

Amikacin is more nephrotoxic than streptomycin, causing renal impairment in 8.7 % of treated patients versus 2 % with streptomycin. (Comparative cohort) 9
Among amikacin, kanamycin, and streptomycin, streptomycin shows the lowest association with hearing loss. (Comparative analysis) 10

For elderly patients (≥ 60 years), reduce the amikacin dose to 10 mg/kg per day (maximum 750 mg). (Dose‑optimization recommendation) 9
In renal insufficiency, keep the total daily dose at 12–15 mg/kg but extend the dosing interval to 2–3 times per week rather than lowering the milligram amount. (Renal‑adjusted dosing guidance) 9
When extending dosing intervals, never decrease the per‑dose amount below 12–15 mg/kg, as sub‑therapeutic concentrations diminish the concentration‑dependent bactericidal effect. (Pharmacodynamic principle) 9

Amikacin’s greater cochleotoxicity relative to tobramycin and gentamicin should be weighed against antimicrobial susceptibility and infection severity; meticulous dosing, therapeutic drug monitoring, and serial audiometry are essential to detect toxicity early. (Combined recommendation from public‑health and respiratory societies) 9, 10